Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Join Canadian Insider Club or Club Ultra to Keep Your Edge

Times are changing, ad revenues are plunging, and Canadian data costs have jumped.

Starting this summer, we will be limiting Canadian company page views to 10 per month for non-members.

Canadian Insider Club members will continue to get Google ad-free and unlimited access to canadianinsider.com.

Join the club to keep your edge! For a limited time, use coupon code SAVE99 to save $99* off a Canadian Insider Club Membership.

*Save $99 on the first year of a new Canadian Insider Club or Canadian Insider Club Ultra membership. Subsequent auto-renewals will be at the standard rate unless canceled. Limited time offer.

Devonian Health Group Inc. (V:GSD)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for GSD within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 30, 2020 16:30 ET
Devonian Announces Correction to Press Release Issued July 28, 2020
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today that a correction had to be made to the press release issued on July 28, 2020, concerning the granting of stock options:
Read full article
Jul 28, 2020 08:45 ET
Devonian Announces the Issuance of Units in Settlement of Interests Owed to a Debenture Holder and Stock Option Grants
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the issuance of the following units in settlement of interests owed to a holder of debentures issued in the private placement, as announced by press releases dated July 19, 2018:
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
4.07
6.51
9.21
Price to Book - most recent quarter
1.16
2.67
2.72
Price to Cash Flow per share - TTM
--
18.19
13.31
Price to Free Cash Flow per share - TTM
--
5.80
18.73
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 202015,000-28,000
Jun 30, 202043,00042,323
Jun 15, 2020677-41,332
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Devonian Health Group In is a late stage Canada-based botanical and pharmaceutical company. The Company adopts a therapeutic approach, which targets various worldwide unmet medical needs. The core business of the Company is the development of prescription botanical drugs, as well as derma-cosmeceutical products, which is divided into two main segments: Therapeutics and Derma-cosmeceuticals. The Therapeutics segment includes Thykamine, which is an active lead drug candidate confirmed in a number of pre-clinical and clinical studies targeting inflammation. The Derma-cosmeceuticals includes the first derma-cosmeceutical product of the Company, which is a women's anti-aging treatment consisting of day, night and eye creams.

See business summary

 

Twitter

Search (past week) for $GSD.CA GSD.V

  • No tweets found